HOME >> BIOLOGY >> NEWS
New multiple myeloma treatment induced total remission in 33 percent of patients

A study, lead by Dr. Laura Rosiol, researcher of the Haematooncology Group of Hospital Clnic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations. The aim of this second phase trial was to assess the treatments overall response rate, its toxicity in patients, the possibility of recovery of innate stem cells, and the response kinetics which is calculated by measuring M-protein concentrations in serum and urine. M-protein is associated with myeloma presence.

This research work, conducted in the frame of the PETHEMA network, has been coordinated by Hospital Clnic de Barcelona and had the participation of eight more Spanish hospitals: Hospital Germans Trias i Pujol, Hospital Clnico Salamanca, Hospital de Sant Pau, Hospital Clnico de Madrid, Hospital La Princesa, Hospital 12 de Octubre and Hospital La Fe. A total of 40 patients between 41 and 65 years with newly diagnosed multiple myeloma participated in this study. All of them underwent six treatment cycles with a 10-day break between each, and were administered Bortezomid or Dexamethasone alternately.

This study has showed very relevant facts. The first notable fact is that there was a global reduction of M-protein concentration in both urine and plasma, reflecting a global reduction of tumour cells. Thus, a highly efficient anti-myeloma effect was observed, and the post autologous transplantation response index was favourable: a 94% response, one third of which (33%) was of complete response (CR) and 22% was a very good partial response (VGPR).

Another surprising result was the speed at which the effect was achieved i.e. the highest reduction in M-protein was detected within the first four treatment cycles. It should be mentioned that the first two cycles already caused an 82% reduction. These results set the base for furt
'"/>

Contact: Anna Ramon
comunicacio@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
4-Jun-2007


Page: 1 2

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Research teams uncover risk genes for multiple sclerosis
3. First new multiple sclerosis gene found in 30 years
4. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
5. Risk genes for multiple sclerosis uncovered
6. Obesity found to be a risk factor for multiple myeloma
7. Kaposi sarcoma arises independently from multiple cells
8. New collaborative research reveals chimpanzees can sustain multiple-tradition cultures
9. Testosterone may help men with multiple sclerosis
10. New imaging approach promises insights into multiple sclerosis
11. Study identifies multiple genetic risk factors for prostate cancer

Post Your Comments:
(Date:7/22/2014)... fires started on July 14, 2014, by lightning from a ... Complex consists of four fires: Stokes Fire, Gold Hikes Fire, ... Gold Hikes fires are now one larger fire. The fires ... is currently over 243,000 acres in size. The present ... fire danger. Public and firefighter safety is the priority on ...
(Date:7/22/2014)... on the horizon. Bacteria that produce a therapeutic ... resistance and other adverse effects of a high-fat ... "Of course it,s hard to speculate from mouse ... assistant professor of Pharmacology. "But essentially we,ve prevented ... mice, even though they,re eating a high-fat diet.", ...
(Date:7/22/2014)... Rochelle, NY -- Stem cells offer much promise for ... approaches stem cell survival is poor, limiting their effectiveness. ... the survival and optimize their therapeutic function after transplantation, ... Open Access , a peer-reviewed journal from Mary Ann ... the BioResearch Open Access website . ...
Breaking Biology News(10 mins):Vanderbilt study shows therapeutic bacteria prevent obesity in mice 2
(Date:7/22/2014)... SHENZHEN , Kina, 22. juli 2014 /PRNewswire/ ... et datterselskab af BGI, verdens største genomics-organisation, annoncerede ... exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform. ... for at levere patenterede sekvenseringsteknologier med 99,999 % ... blev købt af BGI i 2013. Mere end ...
(Date:7/22/2014)... en SHENZHEN, China , ... LTD, (BGI Tech), een dochtermaatschappij van BGI, ,s wereld ... wereldwijde introductie aan van een nieuwe service ten behoeve ... meest geavanceerde platform van Complete Genomics. ... binnen de sector in hoog aanzien staat vanwege de ...
(Date:7/22/2014)... 2014 Hussey Copper , a leader ... antimicrobial copper announces Pullman Regional Hospital,s conversion of more ... solid touch surface, at a nominal cost.  This reasonably ... and other bacteria within 2 hours of exposure 1 ... and infectious diseases in its facilities. Pullman ...
(Date:7/22/2014)... , July 22, 2014  Semler Scientific, Inc. ... medical risk assessment company that develops patented products ... evaluating chronic diseases, today announced that it will ... open of U.S. financial markets on July 25, 2014. Doug ... host a conference call at 11 a.m. EDT, July 25, ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
Cached News: